叶酸联合贝那普利治疗高血压合并高同型半胱氨酸血症的临床研究

目的探讨叶酸片联合盐酸贝那普利片治疗高血压合并高同型半胱氨酸血症的临床疗效。方法选择2015年6月—2016年6月北海市人民医院收治的原发性高血压合并高同型半胱氨酸血症患者123例作为研究对象,所有患者随机分为对照组(63例)和治疗组(60例)。对照组口服盐酸贝那普利片,10 mg/次,1次/d。治疗组在对照组的基础上晨起空腹口服叶酸片,0.8 mg/次,1次/d。两组患者均连续治疗3个月。观察两组的临床疗效,比较两组的同型半胱氨酸水平和血压情况。结果治疗后,对照组和治疗组的总有效率分别为84.13%、96.67%,两组比较差异具有统计学意义(P0.05)。治疗后,两组同型半胱氨酸水平均显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组同型半胱氨酸水平明显低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组收缩压(SBP)、舒张压(DBP)和脉压差均显著下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P0.05)。结论叶酸片联合盐酸贝那普利片治疗高血压合并高同型半胱氨酸血症具有较好的临床疗效,能降低同型半胱氨酸水平和血压,安全性较好,具有一定的临床推广应用价值。

Clinical study on folic acid combined with benazepril in treatment of hypertension complicated with hyperhomocysteinemia

Objective To investigate the clinical effect of Folic Acid Tablets combined with Benazepril Hydrochloride Tablets in treatment of hypertension complicated with hyperhomocysteinemia. Methods Patients (123 cases) with hypertension complicated with hyperhomocysteinemia in Beihai People''s Hospital from June 2015 to June 2016 were randomly divided into control group (63 cases) and treatment group (60 cases). Patients in the control group were po administered with Benazepril Hydrochloride Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Folic Acid Tablets on an empty stomach in the morning on the basis of the control group, 0.8 mg/time, once daily. Patients in two groups were treated for 3 months. After treatment, clinical efficacies were evaluated, and homocysteine levels and blood pressures in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 84.13% and 96.67%, respectively, and there was difference between two groups (P < 0.05). After treatment, the homocysteine levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the homocysteine levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, SBP, DBP, and pulse pressure in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Folic Acid Tablets combined with Benazepril Hydrochloride Tablets has clinical curative effect in treatment of hypertension complicated with hyperhomocysteinemia, can decrease homocysteine levels and blood pressure, with good safety, which has a certain clinical application value.